GOLDFLESS, STEPHEN JACOB,葛德勒斯 史蒂芬 雅各伯,BRANDT, CAMERON,布朗特 凯麦隆,布朗特 凱麥隆,BELMONT, BRIAN,波默特 布莱恩,波默特 布萊恩,CROFT, ALEXANDRA,寇特 亚莉珊卓,寇特 亞莉珊卓,HUSS, DAVID JEFFREY,胡斯 大卫 杰佛瑞,胡斯 大衛 傑佛瑞
申请号：
TW108112029
公开号：
TW202005658A
申请日:
2019.04.03
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.本文中提供結合分子，諸如識別或結合諸如在癌細胞上表現之癌症抗原之肽抗原決定基的結合分子，該癌細胞包括經人類乳頭狀瘤病毒(HPV)感染或含有HPV DNA序列之細胞；及/或識別或結合在主要組織相容性複合物(MHC)分子之環境下的HPV 16 E6或E7之肽抗原決定基的結合分子。所提供之結合分子為結合或識別此類肽抗原決定基之T細胞受體(TCR)或抗體，包括其抗原結合片段。本發明進一步關於包含此類結合分子，例如TCR或抗體(及含有該等抗體之嵌合抗原受體)的工程化細胞，及其在授受細胞療法中之用途。
